Mercury Laboratories FY26 Results: Profit Soars 53%, ₹3.50 Dividend Recommended

Net profit ₹4.83 crore; Revenue ₹75.94 crore.

Reader Takeaway: Strong profit growth and dividend hike signal positive performance, but new labor code costs pose a watchpoint.

What just happened

Mercury Laboratories Limited announced its audited standalone financial results for the financial year ended March 31, 2026. The company reported a significant 53.71% increase in net profit after tax, which rose to ₹4.83 crore from ₹3.14 crore in the previous fiscal year. Revenue from operations saw a modest increase of 1.11%, reaching ₹75.94 crore for FY26.

Why this matters

The substantial jump in profitability, outpacing revenue growth, is a positive sign for shareholders. Additionally, the board has recommended a final dividend of ₹3.50 per share (35%), subject to shareholder approval, indicating confidence in the company's financial health and a commitment to returning value.

The company's earnings per share (EPS) improved to ₹40.28 for FY26, up from ₹26.21 in FY25. This enhanced profitability occurred despite an exceptional item loss of ₹0.39 crore related to additional provisions for gratuity and leave liability due to the upcoming implementation of new Labour Codes.

The backstory

Mercury Laboratories operates in the pharmaceutical sector, focusing on a single segment of pharmaceutical products. The company has been consistently reporting its financial results, with an unmodified audit opinion from Naresh & Co. for the current year.

What changes now

With the recommendation of a final dividend, shareholders can anticipate a payout if approved. The proactive provisioning for new labor codes suggests the company is preparing for regulatory changes. Investors will be watching how these new regulations impact operational costs and profitability going forward.

Risks to watch

The implementation of new Labour Codes effective November 21, 2025, has led to an exceptional charge of ₹0.39 crore. While accounted for, the full operational impact of these evolving state-level rules on the company's cost structure and efficiency remains a key factor to monitor.

Peer comparison

While specific peer financial data for FY26 is not yet widely available in this filing, Mercury Laboratories' profit growth of over 53% appears strong. Typically, pharmaceutical companies face competitive pressures and regulatory scrutiny, making consistent profit growth a key differentiator.

Context metrics (time-bound)

• Net Profit Growth (YoY): 53.71% (FY26 vs FY25)
• Revenue Growth (YoY): 1.11% (FY26 vs FY25)
• Recommended Dividend: ₹3.50 per share
• Exceptional Item Loss: ₹0.39 crore (FY26)
• EPS: ₹40.28 (FY26)

What to track next

Investors should track the finalization of state-level rules for the new Labour Codes and their sustained impact on Mercury Laboratories' operational expenses. Monitoring future revenue growth and profit margins will also be crucial.